UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT

PURSUANT TO SECTION 13 OR 15(d) OF THE

SECURITIES EXCHANGE ACT OF 1934

Date of Report (Date of earliest event reported): March 531, 2026

BRIACELL THERAPEUTICS CORP.

(Exact name of registrant as specified in its charter)

British Columbia A1

47-1099599

(State or other jurisdiction

of incorporation or organization)

(I.R.S. Employer

Identification No.)

Suite 300 - 235 15th Street

West Vancouver, BC V7T 2X1

V7T 2X1

(Address of principal executive offices)

(Zip Code)

(604) 921-1810

(Registrant’s telephone number, including area code)

Commission File No. 001-40101

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

☐	Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐	Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐	Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐	Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered under Section 12(b) of the Act:

Title of each class Trading Symbol(s) Name of each exchange on which registered Common Shares, no par value BCTX The Nasdaq Stock Market LLC Warrants to purchase common shares, no par value ~~BCTXZ~~BCTXW The Nasdaq Stock Market LLC ~~Warrants to purchase common shares, no par value BCTXL The Nasdaq Stock Market LLC~~

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR §230.405) or Rule 12b-2 of the Securities Exchange Act of 1934 (17 CFR §240.12b-2).

Emerging growth company ☒

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 57.0701 ~~Submission~~Regulation ofFD ~~Matters to a Vote of Security Holders~~Disclosure.

On March 531, 2026, ~~BriaCell~~BriaPro Therapeutics Corp., ~~(the~~a ~~“Company”)~~subsidiary ~~held~~of ~~its~~BriaCell ~~Annual~~Therapeutics ~~General~~Corp. ~~and Special Meeting of Shareholders~~ (the “~~Meeting~~Company”)~~. As of January 26~~, ~~2026, the date of record for determining the shareholders entitled to vote on the proposals~~ ~~presented~~filed atits ~~the~~unaudited ~~Meeting,~~condensed ~~there~~interim ~~were~~consolidated ~~7,250,487~~financial ~~common~~statements ~~shares~~and ofmanagement’s ~~the~~discussion ~~Company issued~~ and ~~outstanding~~analysis ~~and~~for ~~entitled to vote at~~ the ~~Meeting.~~three Aand ~~total~~six ofmonth ~~3,502,695~~period ~~common~~ended ~~shares~~January ~~of the Company~~31, ~~constituting a quorum~~2026, ~~were~~with ~~represented~~the inBritish ~~person~~Columbia orSecurities byCommission ~~valid~~and ~~proxies~~Alberta atSecurities ~~the Meeting~~Commission. ~~The~~A ~~matters submitted to a vote~~ copy of the ~~Company’s~~condensed ~~shareholders~~interim atconsolidated ~~the~~financial ~~Meeting~~statements ~~are~~and ~~described in the Company~~management’s ~~definitive proxy~~discussion ~~statement~~and ~~filed~~analysis ~~with~~for the three ~~U.S. Securities~~ and ~~Exchange~~six month ~~Commission~~period onended ~~February~~January 1231, 2026~~. The~~ ~~final~~are ~~results~~included ~~for~~as ~~each~~Exhibit of99.1 ~~the~~and ~~matters~~Exhibit ~~submitted~~99.2 to athis ~~vote~~Current ofReport ~~the~~on ~~Company’s~~Form ~~shareholders~~8-K atand ~~the Meeting~~ are asincorporated herein ~~follows:~~by reference.

~~Proposal~~The 1.information Atfurnished ~~the~~pursuant ~~Meeting,~~to ~~the~~this ~~shareholders~~Item ~~ratified~~7.01, ~~the~~including ~~appointment~~Exhibit of99.1 ~~MNP~~and ~~LLP~~Exhibit as99.2, ~~auditors~~shall ~~for~~not ~~the~~be ~~Company~~deemed ~~and~~“filed” ~~the~~for purposes ~~authorization~~of Section 18 of the ~~Board~~ ofSecurities ~~Directors~~Exchange Act of ~~the~~1934, ~~Company~~as amended (the “~~Board~~Exchange Act”), toor ~~fix~~otherwise subject to the liabilities ~~auditors’~~under ~~remuneration~~that Section and ~~terms~~shall not be deemed to be incorporated by reference into any filing of ~~engagement.~~the ~~The~~Company ~~result~~under the Securities Act of 1933 (the ~~votes~~“Securities toAct”) ~~ratify~~or the ~~appointment~~Exchange Act, regardless of ~~MNP~~any ~~LLP~~general ~~was~~incorporation aslanguage ~~follows:~~in such filings.

For		Withhold		Broker Non-Votes
3,431,761		70,934		0

Item 9.01 Condensed interim financial statements and Exhibits

Proposal 2. At the Meeting, the terms of six (6) members of the Board expired. Each of the six (6) nominees for director (the “Nominees”) were elected to serve until the next annual and special meeting of shareholders, or until his/her successor is duly elected or appointed, unless he/she resigns, is removed, or becomes disqualified in accordance with the Articles of the Company, as amended and in effect, or the Business Corporations Act (British Columbia). The result of the votes to elect the Nominees was as follows:

Directors	For	Withhold	Broker Non-Votes
Dr. Jane Gross	1,837,220	49,810	1,615,665
Mr. Jamieson Bondarenko	1,847,842	39,188	1,615,665
Dr. William V. Williams	1,837,675	49,355	1,615,665
Dr. Rebecca Taub	1,837,729	49,301	1,615,665
Mr. Vaughn C. Embro-Pantalony	1,847,644	39,386	1,615,665
Mr. Martin Schmieg	1,844,132	42,898	1,615,665

Proposal 3. At the Meeting, the Company’s shareholders re-approved the Company’s omnibus equity incentive plan (the “Omnibus Equity Incentive Plan”). The result of the votes to re-approve the Omnibus Equity Incentive Plan was as follows:

For		Against		Broker Non-Votes
1,524,081		362,949		1,615,665

EXHIBIT INDEX

Exhibit		Description
Exhibit No.
10.1		Omnibus Equity Incentive Plan (incorporated by reference from Schedule I to the Definitive Proxy Statement on Schedule 14A of the Company, filed with the SEC on February 12, 2026).
99.1		BriaPro Therapeutics Corp. Unaudited Condensed interim consolidated financial statements for the three and six month period ended January 31, 2026.
99.2		BriaPro Therapeutics Corp. Management’s Discussion and Analysis for the three and six month period ended January 31, 2026.
104		Cover Page Interactive Data File (embedded within the Inline XBRL document)

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

	BRIACELL THERAPEUTICS CORP.
	/s/ William V. Williams
March 9, 2026	William V. Williams
March 31, 2026	William V. Williams
	President and Chief Executive Officer

Filing Compare · BriaCell Therapeutics Corp.